Evidence map›Paper›PMID 31527063›Full record

ArticleBioscience reports2019

A novel benzoxazinone derivative YLT-LL-11 inhibits diffuse large B-cell lymphoma growth via inducing cell cycle arrest and apoptosis.

Cuiting Peng, Changzhen Sun, Ningyu Wang, Yuanmin He, Jixiang Xu, Yongqiong Deng, Lanyang Gao, Jianqiao Zhong, Xia Xiong, Li Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioscience reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Cuiting PengDepartment of dermatology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Changzhen SunDrug Research Center of Integrated Traditional Chinese and Western Medicine, Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China.
Ningyu WangSchool of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China.
Yuanmin HeDepartment of dermatology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Jixiang XuDepartment of dermatology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Yongqiong DengDepartment of dermatology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Lanyang GaoDepartment of Science and Technology, The affiliated hospital of Southwest Medical University, Luzhou, China.
Jianqiao ZhongDepartment of dermatology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Xia XiongDepartment of dermatology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Li LiuDepartment of dermatology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Affiliated Hospital of Southwest Medical University · CNSichuan University · CNSouthwest Jiaotong University · CNSouthwest Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a clinically aggressive B-cell non-Hodgkin's lymphoma (NHL) with high treatment difficulty and high relapse rate. The bromodomain and extra-terminal (BET) proteins play significant roles in supporting the transcription of known DLBCL oncogene MYC, which provides a way for the development of targeted therapeutic agents to address this kind of malignant tumor. Here, we reported a novel benzoxazinone derivative YLT-LL-11 as potential BRD4 inhibitor and further investigated the biological activities against DLBCL. The results suggested that YLT-LL-11 inhibited cell growth against a panel of human hematopoietic malignancies cell lines in a dose- and time-dependent manner. In addition, flow cytometry and Western blotting assays showed that YLT-LL-11 inhibited the proliferation of a DLBCL cell line OCI-LY10 via inducing G0/G1 cell cycle arrest with regulation of the cyclin-dependent kinases (CDKs) expression. Furthermore, YLT-LL-11 facilitated OCI-LY10 cell apoptosis by up-regulation of pro-apoptotic protein BAX and down-regulation of anti-apoptotic protein Bcl-2. Taken together, these results revealed that BRD4 inhibitor YLT-LL-11 can down-regulate growth-associated transcription factors MYC in DLBCL thus resulted in cell growth inhibition and apoptosis.

Indexed as

AnimalsApoptosisBenzoxazinesCell Cycle CheckpointsChlorocebus aethiopsCOS CellsHEK293 CellsHematologic NeoplasmsHumansLymphoma, Large B-Cell, DiffuseProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycBCL2 protein, humanBenzoxazinesMYC protein, humanProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycapoptosisBRD4cell cycleDiffuse large B cell lymphoma

Identifiers

PMID31527063
PMCPMC6822579
OpenAlexW3001440840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.